PharmAust (ASX:PAA) has announced the arrival of its cGMP (current Good Manufacturing Practice) grade monepantel (MPL) tablets specifically designed for the MND trial in Melbourne.
The trial is being funded with support from FightMND.
The cGMP MPL tablets for MND were designed in a different shape and size to help swallowing by MND patients and to reach specific blood drug levels targeted for this disease.
Pre-release technical specifications of the MPL tablets demonstrate that stability specification required for the trial is achieved and PharmAust is now awaiting signed technical documentation from the manufacturer.
PharmAust's chief scientific officer Dr Richard Mollard said, "It is a terrific milestone to have MPL tablets designed specifically for this trial on-site. With the remaining preparations near completion, discussions with potential accruals will be formally commenced once hospital governance is signed. We are grateful to FightMND for $881,085 funding for this trial and for its continual support."
